Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected to show no change in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Iteos Therapeutics Inc is for a loss of $1.06 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Iteos Therapeutics Inc is $21.39, above its last closing price of $6.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.15 | -0.89 | -1.05 | Missed | -18.1 |
Jun. 30 2024 | -1.04 | -1.04 | -0.18 | Beat | 82.7 |
Mar. 31 2024 | -0.97 | -1.26 | -1.07 | Beat | 14.8 |
Dec. 31 2023 | -0.93 | -1.03 | -0.85 | Beat | 17.7 |
Sep. 30 2023 | -1.14 | -1.20 | -0.90 | Beat | 25.2 |
Jun. 30 2023 | -0.98 | -1.03 | -0.96 | Beat | 6.8 |
Mar. 31 2023 | -1.00 | -0.99 | -0.44 | Beat | 55.8 |
Dec. 31 2022 | 0.33 |
This summary was machine generated March 5 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。